No Data
Beijing Strong Biotechnologies, Inc. (300406.SZ) has obtained a registration certificate for a medical instrument.
Beijing Strong Biotechnologies, Inc. (300406.SZ) announced that the company has received the "Medical Device Registration Certificate" issued by the Beijing Municipal Bureau of Pharmaceutical Affairs...
Beijing Strong Biotechnologies, Inc. (300406.SZ): China National Pharmaceutical Investment has cumulatively increased its Shareholding by 4.3408 million shares, and the increase has been completed.
On December 24, Gelonghui reported that Beijing Strong Biotechnologies, Inc. (300406.SZ) announced that on December 24, 2024, it received a letter from China Meheco Group, a shareholder holding more than 5% of the shares, regarding the implementation of the Shareholding plan. As of the date of this announcement, the Shareholding plan has been completed, with China Meheco Group increasing its shares by a total of 4,340,800 shares through centralized bidding, accounting for 0.74% of the company's shares with voting rights, with an increase amounting to 62,283,792.00 yuan.
Beijing Strong Biotechnologies, Inc. (300406.SZ) obtained multiple medical instruments registration certificates.
Beijing Strong Biotechnologies, Inc. (300406.SZ) announced that the company has received the "Medical Device Registration Certificate" issued by the Beijing Municipal Bureau of Pharmaceutical Affairs...
Jiujiang Biotech: Report for the third quarter of 2024
Beijing Strong Biotechnologies, Inc. (300406.SZ) released its performance for the first three quarters, with a net income of 0.373 billion yuan, a 0.56% increase.
Beijing Strong Biotechnologies, Inc. (300406.SZ) released its third quarter report for 2024, with the company's revenue for the first three quarters reaching 1...
beijing strong biotechnologies, inc. (300406.SZ): net income of 0.373 billion yuan in the first three quarters, a year-on-year increase of 0.56%.
On October 28th, Beijing Strong Biotechnologies, Inc. (300406.SZ) released its third quarter report for 2024. The company achieved revenue of 1.237 billion yuan in the first three quarters, a year-on-year increase of 0.30%; net income attributable to shareholders of the listed company was 0.373 billion yuan, a year-on-year increase of 0.56%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.371 billion yuan, a year-on-year increase of 0.63%; with basic earnings per share of 0.63 yuan.
